FDA warned True Earth Health Products over Plexaderm Dark Spot Fade Gel, an unapproved, misbranded hydroquinone skin-bleaching drug.
What happened
FDA reviewed the product label and the Sheerscience.com website, where Plexaderm Skincare DARK SPOT FADE GEL is available for purchase. FDA found claims that the product treats hyperpigmentation, skin discoloration, and age spots, and the label lists hydroquinone 2% as a skin lightener. FDA determined the product is an unapproved new drug and misbranded because no FDA-approved application is in effect and it does not comply with section 505G.
What FDA found
The product is an unapproved new drug because it was introduced into interstate commerce without an FDA-approved application.
FD&C Act section 505(a), 21 U.S.C. 355(a)The product is misbranded because it is deemed misbranded under section 505G(a)(4) and lacks an approved application or 505G compliance.
FD&C Act section 502(ee), 21 U.S.C. 352(ee); section 505G(a)(4), 21 U.S.C. 355h(a)(4)The label and website claims show the product is intended to treat hyperpigmentation, skin discoloration, and age spots and to affect the skin, making it a drug.
FD&C Act section 201(g)(1)(B)/(C), 21 U.S.C. 321(g)(1)(B)/(C); 21 CFR 201.128FDA determined in a proposed rule that over-the-counter skin bleaching drugs, including those with hydroquinone, are not generally recognized as safe and effective.
21 CFR part 330; 71 FR 51146
What FDA wants
FDA tells the company to respond in writing within 15 working days, specify what it has done to correct the violations and prevent recurrence, and if it cannot complete corrections, state the reasons for delay and a schedule for completion.
Who should pay attention
- online skincare brands selling hydroquinone products
- marketers and distributors of over-the-counter skin lighteners
- regulatory teams for e-commerce skincare sellers
This is a summary. Read the original letter on fda.gov.